Plain-English translation of NCT06752785 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing CD19/CD22 CAR-T cell therapy, a personalized treatment where doctors collect your child's own immune cells, engineer them in the laboratory to recognize and attack leukemia cells, and then give them back as an infusion. The trial is specifically for children whose leukemia has not completely gone away after the first phase of standard chemotherapy. Researchers want to see if this treatment is safe and effective at helping these children reach remission.
Some children with acute lymphoblastic leukemia don't respond well enough to standard chemotherapy alone, meaning cancer cells remain detectable in their bone marrow. This trial exists to find a new option for these children by testing whether engineered immune cells can succeed where traditional drugs have had limited success.
You likely qualify if…
You likely don't qualify if…
Your child will first have immune cells collected through a blood process. These cells are then sent to a laboratory to be engineered over a few weeks. Meanwhile, your child receives chemotherapy to prepare their body. Once the engineered cells are ready, they are given back through an IV infusion. After that, your child will have frequent check-ups — visits on days 7, 14, 21, and 30, then monthly visits for 6 months, then every 3 months for up to 2 years, and annual visits afterward. Your child will also continue standard chemotherapy as planned. The entire active treatment phase takes about a month, but follow-up continues for years.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China